



Clinical trial results:

An Open-label Phase 1/2a Study of Oral BAL101553 in Adult Patients With Advanced Solid Tumors and in Adult Patients With Recurrent or Progressive Glioblastoma or High-grade Glioma

Summary

EudraCT number	2014-003371-34
Trial protocol	GB DE BE
Global end of trial date	24 November 2022

Results information

Result version number	v1 (current)
This version publication date	16 November 2023
First version publication date	16 November 2023

Trial information

Trial identification

Sponsor protocol code	CDI-CS-002
-----------------------	------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02490800
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Basilea Pharmaceutica International Ltd, Allschwil
Sponsor organisation address	Hegenheimermattweg 167b, Allschwil, Switzerland, 4123
Public contact	Thomas Kaindl, MD, Basilea Pharmaceutica International Ltd, Allschwil, +41 61 567 15 24, thomas.kaindl@basilea.com
Scientific contact	Thomas Kaindl, MD, Basilea Pharmaceutica International Ltd, Allschwil, +41 61 567 15 24, thomas.kaindl@basilea.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	16 December 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	30 September 2022
Global end of trial reached?	Yes
Global end of trial date	24 November 2022
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To determine the maximum tolerated dose (MTD) and to characterize dose-limiting toxicities (DLTs) of daily oral lisavanbulin, administered to adults with advanced or recurrent solid tumors who have failed standard therapy, or for whom no effective standard therapy is available, and to patients with recurrent or progressive glioblastoma (GBM) or high-grade glioma (HGG).

Protection of trial subjects:

The study was conducted according to the ethical principles that have their origins in the World Medical Association's Declaration of Helsinki, the International Council for Harmonisation (ICH) E6 Good Clinical Practice, and all applicable national and local laws and regulations for the conduct of clinical research and the protection of personal data. If conflicts between local laws and regulations arose, the more stringent requirements were adopted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 May 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 63
Country: Number of subjects enrolled	Belgium: 2
Country: Number of subjects enrolled	Switzerland: 4
Country: Number of subjects enrolled	Germany: 3
Worldwide total number of subjects	72
EEA total number of subjects	5

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	0
Adults (18-64 years)	53
From 65 to 84 years	19
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

In the Phase 1 study, a total of 29 screening-failures occurred. Thus, a total of 72 patients with advanced solid tumors, recurrent or progressive glioblastoma (GBM) or high-grade glioma (HGG) were enrolled in this Phase 1 and Phase 2a study.

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Phase 1 patients with solid tumors: Lisavanbulin 2 mg

Arm description:

Solid tumor patients treated with lisavanbulin 2 mg/day in the dose escalation portion of the study

Arm type	Experimental
Investigational medicinal product name	Lisavanbulin
Investigational medicinal product code	BAL101553
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Lisavanbulin 2 mg was given orally once daily to fasted patients until disease progression, unacceptable toxicity, or other discontinuation criteria were met.

Arm title	Phase 1 patients with solid tumors: Lisavanbulin 4 mg
------------------	---

Arm description:

Solid tumor patients treated with lisavanbulin 4 mg/day in the dose escalation portion of the study

Arm type	Experimental
Investigational medicinal product name	Lisavanbulin
Investigational medicinal product code	BAL101553
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Lisavanbulin 4 mg was given orally once daily to fasted patients until disease progression, unacceptable toxicity, or other discontinuation criteria were met.

Arm title	Phase 1 patients with solid tumors: Lisavanbulin 8 mg
------------------	---

Arm description:

Solid tumor patients treated with lisavanbulin 8 mg/day in the dose escalation portion of the study

Arm type	Experimental
Investigational medicinal product name	Lisavanbulin
Investigational medicinal product code	BAL101553
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Lisavanbulin 8 mg was given orally once daily to fasted patients until disease progression, unacceptable toxicity, or other discontinuation criteria were met.

Arm title	Phase 1 patients with solid tumors: Lisavanbulin 16 mg
------------------	--

Arm description:

Solid tumor patients treated with lisavanbulin 16 mg/day in the dose escalation portion of the study

Arm type	Experimental
Investigational medicinal product name	Lisavanbulin
Investigational medicinal product code	BAL101553
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Lisavanbulin 16 mg was given orally once daily to fasted patients until disease progression, unacceptable toxicity, or other discontinuation criteria were met.

Arm title	Phase 1 patients with solid tumors: Lisavanbulin 20 mg
------------------	--

Arm description:

Solid tumor patients treated with lisavanbulin 20 mg/day in the dose escalation portion of the study

Arm type	Experimental
Investigational medicinal product name	Lisavanbulin
Investigational medicinal product code	BAL101553
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Lisavanbulin 20 mg was given orally once daily to fasted patients until disease progression, unacceptable toxicity, or other discontinuation criteria were met.

Arm title	Phase 1 patients with solid tumors: Lisavanbulin 30 mg
------------------	--

Arm description:

Solid tumor patients treated with lisavanbulin 30 mg/day in the dose escalation portion of the study

Arm type	Experimental
Investigational medicinal product name	Lisavanbulin
Investigational medicinal product code	BAL101553
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Lisavanbulin 30 mg was given orally once daily to fasted patients until disease progression, unacceptable toxicity, or other discontinuation criteria were met.

Arm title	Phase 1 patients with GBM / HGG: Lisavanbulin 8 mg
------------------	--

Arm description:

HGG and GBM patients treated with lisavanbulin 8 mg/day in the dose escalation portion of the study

Arm type	Experimental
Investigational medicinal product name	Lisavanbulin
Investigational medicinal product code	BAL101553
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Lisavanbulin 8 mg was given orally once daily to fasted patients until disease progression, unacceptable toxicity, or other discontinuation criteria were met.

Arm title	Phase 1 patients with GBM / HGG: Lisavanbulin 15 mg
------------------	---

Arm description:

HGG and GBM patients treated with lisavanbulin 15 mg/day in the dose escalation portion of the study

Arm type	Experimental
Investigational medicinal product name	Lisavanbulin
Investigational medicinal product code	BAL101553
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Lisavanbulin 15 mg was given orally once daily to fasted patients until disease progression, unacceptable toxicity, or other discontinuation criteria were met.

Arm title	Phase 1 patients with GBM / HGG: Lisavanbulin 20 mg
------------------	---

Arm description:

HGG and GBM patients treated with lisavanbulin 20 mg/day in the dose escalation portion of the study

Arm type	Experimental
Investigational medicinal product name	Lisavanbulin
Investigational medicinal product code	BAL101553
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Lisavanbulin 20 mg was given orally once daily to fasted patients until disease progression, unacceptable toxicity, or other discontinuation criteria were met.

Arm title	Phase 1 patients with GBM / HGG: Lisavanbulin 25 mg
------------------	---

Arm description:

HGG and GBM patients treated with lisavanbulin 25 mg/day in the dose escalation portion of the study

Arm type	Experimental
Investigational medicinal product name	Lisavanbulin
Investigational medicinal product code	BAL101553
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Lisavanbulin 25 mg was given orally once daily to fasted patients until disease progression, unacceptable toxicity, or other discontinuation criteria were met.

Arm title	Phase 1 patients with GBM / HGG: Lisavanbulin 30 mg
------------------	---

Arm description:

HGG and GBM patients treated with lisavanbulin 30 mg/day in the dose escalation portion of the study

Arm type	Experimental
Investigational medicinal product name	Lisavanbulin
Investigational medicinal product code	BAL101553
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Lisavanbulin 30 mg was given orally once daily to fasted patients until disease progression, unacceptable toxicity, or other discontinuation criteria were met.

Arm title	Phase 1 patients with GBM / HGG: Lisavanbulin 35 mg
Arm description: HGG and GBM patients treated with lisavanbulin 35 mg/day in the dose escalation portion of the study	
Arm type	Experimental
Investigational medicinal product name	Lisavanbulin
Investigational medicinal product code	BAL101553
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Lisavanbulin 35 mg was given orally once daily to fasted patients until disease progression, unacceptable toxicity, or other discontinuation criteria were met.

Arm title	Phase 2a patients with GBM: Lisavanbulin 25 mg
Arm description: GBM patients treated with lisavanbulin 25 mg/day in the dose expansion portion of the study	
Arm type	Experimental
Investigational medicinal product name	Lisavanbulin
Investigational medicinal product code	BAL101553
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Lisavanbulin 25 mg was given orally once daily to fasted patients until disease progression, unacceptable toxicity, or other discontinuation criteria were met.

Number of subjects in period 1	Phase 1 patients with solid tumors: Lisavanbulin 2 mg	Phase 1 patients with solid tumors: Lisavanbulin 4 mg	Phase 1 patients with solid tumors: Lisavanbulin 8 mg
Started	3	3	3
Completed	0	0	0
Not completed	3	3	3
Consent withdrawn by subject	-	-	-
Patient enrolled in post-trial access	-	-	-
Adverse event, non-fatal	-	-	-
Progressive disease	3	3	3

Number of subjects in period 1	Phase 1 patients with solid tumors: Lisavanbulin 16 mg	Phase 1 patients with solid tumors: Lisavanbulin 20 mg	Phase 1 patients with solid tumors: Lisavanbulin 30 mg
Started	7	7	3
Completed	0	0	0
Not completed	7	7	3
Consent withdrawn by subject	1	-	-

Patient enrolled in post-trial access	-	-	-
Adverse event, non-fatal	2	3	2
Progressive disease	4	4	1

Number of subjects in period 1	Phase 1 patients with GBM / HGG: Lisavanbulin 8 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 15 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 20 mg
Started	4	3	7
Completed	0	0	0
Not completed	4	3	7
Consent withdrawn by subject	-	-	1
Patient enrolled in post-trial access	-	-	-
Adverse event, non-fatal	-	-	-
Progressive disease	4	3	6

Number of subjects in period 1	Phase 1 patients with GBM / HGG: Lisavanbulin 25 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 30 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 35 mg
Started	3	8	3
Completed	0	0	0
Not completed	3	8	3
Consent withdrawn by subject	-	-	-
Patient enrolled in post-trial access	1	1	-
Adverse event, non-fatal	-	-	2
Progressive disease	2	7	1

Number of subjects in period 1	Phase 2a patients with GBM: Lisavanbulin 25 mg
Started	18
Completed	0
Not completed	18
Consent withdrawn by subject	-
Patient enrolled in post-trial access	6
Adverse event, non-fatal	2
Progressive disease	10

Baseline characteristics

Reporting groups

Reporting group title	Phase 1 patients with solid tumors: Lisavanbulin 2 mg
Reporting group description:	
Solid tumor patients treated with lisavanbulin 2 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 1 patients with solid tumors: Lisavanbulin 4 mg
Reporting group description:	
Solid tumor patients treated with lisavanbulin 4 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 1 patients with solid tumors: Lisavanbulin 8 mg
Reporting group description:	
Solid tumor patients treated with lisavanbulin 8 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 1 patients with solid tumors: Lisavanbulin 16 mg
Reporting group description:	
Solid tumor patients treated with lisavanbulin 16 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 1 patients with solid tumors: Lisavanbulin 20 mg
Reporting group description:	
Solid tumor patients treated with lisavanbulin 20 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 1 patients with solid tumors: Lisavanbulin 30 mg
Reporting group description:	
Solid tumor patients treated with lisavanbulin 30 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 1 patients with GBM / HGG: Lisavanbulin 8 mg
Reporting group description:	
HGG and GBM patients treated with lisavanbulin 8 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 1 patients with GBM / HGG: Lisavanbulin 15 mg
Reporting group description:	
HGG and GBM patients treated with lisavanbulin 15 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 1 patients with GBM / HGG: Lisavanbulin 20 mg
Reporting group description:	
HGG and GBM patients treated with lisavanbulin 20 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 1 patients with GBM / HGG: Lisavanbulin 25 mg
Reporting group description:	
HGG and GBM patients treated with lisavanbulin 25 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 1 patients with GBM / HGG: Lisavanbulin 30 mg
Reporting group description:	
HGG and GBM patients treated with lisavanbulin 30 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 1 patients with GBM / HGG: Lisavanbulin 35 mg
Reporting group description:	
HGG and GBM patients treated with lisavanbulin 35 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 2a patients with GBM: Lisavanbulin 25 mg
Reporting group description:	
GBM patients treated with lisavanbulin 25 mg/day in the dose expansion portion of the study	

Reporting group values	Phase 1 patients with solid tumors: Lisavanbulin 2 mg	Phase 1 patients with solid tumors: Lisavanbulin 4 mg	Phase 1 patients with solid tumors: Lisavanbulin 8 mg
Number of subjects	3	3	3
Age categorical			
Units: Subjects			
In utero			

Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: years arithmetic mean standard deviation	51.3 ± 21.94	66.7 ± 10.50	63.3 ± 6.51
Gender categorical Units: Subjects			
Female	2	2	1
Male	1	1	2
Race Units: Subjects			
Asian	0	0	0
Black or African American	0	0	0
White	3	3	3

Reporting group values	Phase 1 patients with solid tumors: Lisavanbulin 16 mg	Phase 1 patients with solid tumors: Lisavanbulin 20 mg	Phase 1 patients with solid tumors: Lisavanbulin 30 mg
Number of subjects	7	7	3
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: years arithmetic mean standard deviation	61.0 ± 16.55	64.4 ± 7.00	65.7 ± 12.06
Gender categorical Units: Subjects			
Female	5	6	0
Male	2	1	3
Race Units: Subjects			
Asian	0	0	0
Black or African American	0	0	0
White	7	7	3

Reporting group values	Phase 1 patients with GBM / HGG: Lisavanbulin 8 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 15 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 20 mg
Number of subjects	4	3	7
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: years			
arithmetic mean	53.8	53.7	42.3
standard deviation	± 9.95	± 7.77	± 9.62
Gender categorical Units: Subjects			
Female	2	2	3
Male	2	1	4
Race Units: Subjects			
Asian	0	0	0
Black or African American	1	0	0
White	3	3	7

Reporting group values	Phase 1 patients with GBM / HGG: Lisavanbulin 25 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 30 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 35 mg
Number of subjects	3	8	3
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: years			
arithmetic mean	45.3	53.6	51.3
standard deviation	± 11.50	± 9.78	± 16.74

Gender categorical			
Units: Subjects			
Female	2	2	1
Male	1	6	2
Race			
Units: Subjects			
Asian	0	1	1
Black or African American	0	0	0
White	3	7	2

Reporting group values	Phase 2a patients with GBM: Lisavanbulin 25 mg	Total	
Number of subjects	18	72	
Age categorical			
Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous			
Units: years			
arithmetic mean	55.6		
standard deviation	± 10.43	-	
Gender categorical			
Units: Subjects			
Female	3	31	
Male	15	41	
Race			
Units: Subjects			
Asian	0	2	
Black or African American	0	1	
White	18	69	

End points

End points reporting groups

Reporting group title	Phase 1 patients with solid tumors: Lisavanbulin 2 mg
Reporting group description:	
Solid tumor patients treated with lisavanbulin 2 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 1 patients with solid tumors: Lisavanbulin 4 mg
Reporting group description:	
Solid tumor patients treated with lisavanbulin 4 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 1 patients with solid tumors: Lisavanbulin 8 mg
Reporting group description:	
Solid tumor patients treated with lisavanbulin 8 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 1 patients with solid tumors: Lisavanbulin 16 mg
Reporting group description:	
Solid tumor patients treated with lisavanbulin 16 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 1 patients with solid tumors: Lisavanbulin 20 mg
Reporting group description:	
Solid tumor patients treated with lisavanbulin 20 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 1 patients with solid tumors: Lisavanbulin 30 mg
Reporting group description:	
Solid tumor patients treated with lisavanbulin 30 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 1 patients with GBM / HGG: Lisavanbulin 8 mg
Reporting group description:	
HGG and GBM patients treated with lisavanbulin 8 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 1 patients with GBM / HGG: Lisavanbulin 15 mg
Reporting group description:	
HGG and GBM patients treated with lisavanbulin 15 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 1 patients with GBM / HGG: Lisavanbulin 20 mg
Reporting group description:	
HGG and GBM patients treated with lisavanbulin 20 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 1 patients with GBM / HGG: Lisavanbulin 25 mg
Reporting group description:	
HGG and GBM patients treated with lisavanbulin 25 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 1 patients with GBM / HGG: Lisavanbulin 30 mg
Reporting group description:	
HGG and GBM patients treated with lisavanbulin 30 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 1 patients with GBM / HGG: Lisavanbulin 35 mg
Reporting group description:	
HGG and GBM patients treated with lisavanbulin 35 mg/day in the dose escalation portion of the study	
Reporting group title	Phase 2a patients with GBM: Lisavanbulin 25 mg
Reporting group description:	
GBM patients treated with lisavanbulin 25 mg/day in the dose expansion portion of the study	
Subject analysis set title	MTD-evaluable patients with solid tumors
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
All patients who received at least one dose of lisavanbulin and experienced a DLT, or received at least 24 doses without experiencing a DLT during the first 28 days.	
Subject analysis set title	MTD-evaluable patients with GBM or HGG
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
All patients who received at least one dose of lisavanbulin and experienced a DLT, or received at least	

Primary: Phase 1: Maximum tolerated dose (MTD) of daily oral lisavanbulin

End point title	Phase 1: Maximum tolerated dose (MTD) of daily oral lisavanbulin ^[1]
-----------------	---

End point description:

MTD: highest dose level of lisavanbulin at which no more than 1 of 6 MTD-evaluable subjects experienced dose limiting toxicities (DLT).

End point type	Primary
----------------	---------

End point timeframe:

During first 28 day cycle

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As the endpoint is descriptive in nature, no statistical analysis is provided.

End point values	MTD-evaluable patients with solid tumors	MTD-evaluable patients with GBM or HGG		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	23	24		
Units: mg				
number (not applicable)				
MTD of daily oral lisavanbulin	16	30		

Statistical analyses

No statistical analyses for this end point

Primary: Phase 2a: Objective Response Rate (ORR)

End point title	Phase 2a: Objective Response Rate (ORR) ^{[2][3]}
-----------------	---

End point description:

The ORR was calculated as the proportion of patients (rate) with complete or partial responses and its 95% Confidence Interval (CI) based on RANO criteria.

End point type	Primary
----------------	---------

End point timeframe:

Assessed every 8 weeks from time of first dose until disease progression.

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As the endpoint is descriptive in nature, no statistical analysis is provided.

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This primary endpoint only applies to Phase 2a.

End point values	Phase 2a patients with GBM: Lisavanbulin 25 mg			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: proportion of patients (rate)				
number (confidence interval 95%)	11.1 (0.3 to 48.2)			

Statistical analyses

No statistical analyses for this end point

Primary: Phase 2a: Best objective response

End point title	Phase 2a: Best objective response ^[4] ^[5]
-----------------	---

End point description:

The best objective response in patients with measurable disease at baseline and at least one "radiological assessment in neuro-oncology (RANO)" after 6 weeks of study treatment.

End point type	Primary
----------------	---------

End point timeframe:

Assessed every 8 weeks from time of first dose until disease progression.

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As the endpoint is descriptive in nature, no statistical analysis is provided.

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This primary endpoint only applies to Phase 2a.

End point values	Phase 2a patients with GBM: Lisavanbulin 25 mg			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: Number of patients				
Complete response	0			
Partial response	1			
Stable disease	4			
Progressive disease	4			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Patients With CTCAE Grade 3-4 TEAEs

End point title	Number of Patients With CTCAE Grade 3-4 TEAEs
-----------------	---

End point description:

Number of patients experiencing treatment-emergent adverse events (TEAE) of CTCAE Grade 3 or 4.

End point type	Secondary
----------------	-----------

End point timeframe:

TEAEs were defined as all events occurring after lisavanbulin treatment began and up to 28 days after last study drug administration.

End point values	Phase 1 patients with solid tumors: Lisavanbulin 2 mg	Phase 1 patients with solid tumors: Lisavanbulin 4 mg	Phase 1 patients with solid tumors: Lisavanbulin 8 mg	Phase 1 patients with solid tumors: Lisavanbulin 16 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	7
Units: Number of patients				
Patients with unrelated TEAEs of Grade 3-4	0	1	0	3
Patients with related TEAEs of Grade 3-4	0	0	1	2
Patients without TEAEs of Grade 3-4	3	2	2	2

End point values	Phase 1 patients with solid tumors: Lisavanbulin 20 mg	Phase 1 patients with solid tumors: Lisavanbulin 30 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 8 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 15 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	3	4	3
Units: Number of patients				
Patients with unrelated TEAEs of Grade 3-4	1	0	1	0
Patients with related TEAEs of Grade 3-4	4	2	0	0
Patients without TEAEs of Grade 3-4	2	1	3	3

End point values	Phase 1 patients with GBM / HGG: Lisavanbulin 20 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 25 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 30 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 35 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	3	8	3
Units: Number of patients				
Patients with unrelated TEAEs of Grade 3-4	1	1	4	0
Patients with related TEAEs of Grade 3-4	0	0	0	1
Patients without TEAEs of Grade 3-4	6	2	4	2

End point values	Phase 2a patients with GBM: Lisavanbulin 25 mg			
Subject group type	Reporting group			
Number of subjects analysed	18			
Units: Number of patients				
Patients with unrelated TEAEs of Grade 3-4	5			
Patients with related TEAEs of Grade 3-4	3			
Patients without TEAEs of Grade 3-4	10			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1: Best Objective Response

End point title	Phase 1: Best Objective Response ^[6]
End point description:	
The best objective response according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for patients with advanced or recurrent solid tumors and based on RANO criteria for patients with recurrent or progressive GBM / HGG.	
End point type	Secondary
End point timeframe:	
Assessed every 8 weeks from time of first dose until disease progression.	
Notes:	
[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.	
Justification: This secondary endpoint only applies to Phase 1.	

End point values	Phase 1 patients with solid tumors: Lisavanbulin 2 mg	Phase 1 patients with solid tumors: Lisavanbulin 4 mg	Phase 1 patients with solid tumors: Lisavanbulin 8 mg	Phase 1 patients with solid tumors: Lisavanbulin 16 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	7
Units: Number of patients				
Complete response	0	0	0	0
Partial response	0	0	0	0
Stable disease	1	0	1	4
Progressive disease	2	3	2	2
Missing	0	0	0	1

End point values	Phase 1 patients with solid tumors: Lisavanbulin 20 mg	Phase 1 patients with solid tumors: Lisavanbulin 30 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 8 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 15 mg
-------------------------	--	--	--	---

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	3	4	3
Units: Number of patients				
Complete response	0	0	0	0
Partial response	0	0	0	0
Stable disease	3	1	0	1
Progressive disease	4	2	4	2
Missing	0	0	0	0

End point values	Phase 1 patients with GBM / HGG: Lisavanbulin 20 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 25 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 30 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 35 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	3	8	3
Units: Number of patients				
Complete response	0	0	1	0
Partial response	0	1	0	0
Stable disease	2	1	1	2
Progressive disease	5	1	5	1
Missing	0	0	1	0

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1: Objective Response Rate (ORR)

End point title	Phase 1: Objective Response Rate (ORR) ^[7]
End point description:	
The ORR was calculated as the proportion of patients (rate) with complete or partial responses and its 95% CI based on RECIST criteria v1.1 for patients with advanced or recurrent solid tumors; and based on RANO criteria for patients with recurrent or progressive GBM / HGG.	
End point type	Secondary
End point timeframe:	
Assessed every 8 weeks from time of first dose until disease progression.	
Notes:	
[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.	
Justification: This secondary endpoint only applies to Phase 1.	

End point values	Phase 1 patients with solid tumors: Lisavanbulin 2 mg	Phase 1 patients with solid tumors: Lisavanbulin 4 mg	Phase 1 patients with solid tumors: Lisavanbulin 8 mg	Phase 1 patients with solid tumors: Lisavanbulin 16 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	7
Units: Proportion of patients (rate)				
number (confidence interval 95%)	0 (0.0 to 70.8)	0 (0.0 to 70.8)	0 (0.0 to 70.8)	0 (0.0 to 41.0)

End point values	Phase 1 patients with solid tumors: Lisavanbulin 20 mg	Phase 1 patients with solid tumors: Lisavanbulin 30 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 8 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 15 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	3	4	3
Units: Proportion of patients (rate)				
number (confidence interval 95%)	0 (0.0 to 41.0)	0 (0.0 to 70.8)	0 (0.0 to 60.2)	0 (0.0 to 70.8)

End point values	Phase 1 patients with GBM / HGG: Lisavanbulin 20 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 25 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 30 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 35 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	3	8	3
Units: Proportion of patients (rate)				
number (confidence interval 95%)	0 (0.0 to 41.0)	33.3 (0.8 to 90.6)	12.5 (0.3 to 52.7)	0 (0.0 to 70.8)

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2a: PFS at 6 Months

End point title	Phase 2a: PFS at 6 Months ^[8]
End point description:	The probability of being event free at 6 months
End point type	Secondary
End point timeframe:	Six months

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint only applies to Phase 2a.

End point values	Phase 2a patients with GBM: Lisavanbulin 25 mg			
Subject group type	Reporting group			
Number of subjects analysed	18			
Units: percent				
number (confidence interval 95%)	31.3 (11.8 to 53.1)			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2a: Progression-free survival (PFS)

End point title	Phase 2a: Progression-free survival (PFS) ^[9]
-----------------	--

End point description:

PFS was defined as the interval between the date of first study drug administration and the earliest date of objective disease progression based on RANO criteria. Patients who have not progressed or died at the end of the study were censored at the time of their latest objective tumor assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

Assessed every 8 weeks from time of first dose until disease progression.

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint only applies to Phase 2a.

End point values	Phase 2a patients with GBM: Lisavanbulin 25 mg			
Subject group type	Reporting group			
Number of subjects analysed	18			
Units: Months				
median (confidence interval 95%)	2.5 (1.4 to 7.5)			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2a: Overall survival (OS) at 12 months

End point title	Phase 2a: Overall survival (OS) at 12 months ^[10]
-----------------	--

End point description:

The probability of surviving for twelve months

End point type	Secondary
----------------	-----------

End point timeframe:

Twelve months

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint only applies to Phase 2a.

End point values	Phase 2a patients with GBM: Lisavanbulin 25 mg			
Subject group type	Reporting group			
Number of subjects analysed	18			
Units: percent				
number (confidence interval 95%)	42.9 (15.9 to 67.8)			

Statistical analyses

No statistical analyses for this end point

Secondary: AUC of avanbulin (BAL27862)

End point title	AUC of avanbulin (BAL27862)
End point description: Area under the plasma concentration time curve from time point zero to the last quantifiable concentration	
End point type	Secondary
End point timeframe: Day 1 of Cycle 1	

End point values	Phase 1 patients with solid tumors: Lisavanbulin 2 mg	Phase 1 patients with solid tumors: Lisavanbulin 4 mg	Phase 1 patients with solid tumors: Lisavanbulin 8 mg	Phase 1 patients with solid tumors: Lisavanbulin 16 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	7
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)	34.040 (± 0.840)	180.060 (± 0.150)	258.460 (± 0.320)	823.980 (± 0.350)

End point values	Phase 1 patients with solid tumors: Lisavanbulin 20 mg	Phase 1 patients with solid tumors: Lisavanbulin 30 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 8 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 15 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	3	4	3
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)	1014.130 (± 0.650)	1649.350 (± 0.250)	230.800 (± 0.800)	692.230 (± 0.160)

End point values	Phase 1 patients with GBM / HGG: Lisavanbulin 20 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 25 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 30 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 35 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	3	8	3
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)	344.540 (\pm 0.580)	575.060 (\pm 0.440)	1055.130 (\pm 0.250)	1264.610 (\pm 0.320)

End point values	Phase 2a patients with GBM: Lisavanbulin 25 mg			
Subject group type	Reporting group			
Number of subjects analysed	18			
Units: h*ng/mL				
geometric mean (geometric coefficient of variation)	713.710 (\pm 0.480)			

Statistical analyses

No statistical analyses for this end point

Secondary: Half-life of avanbulin (BAL27862)

End point title	Half-life of avanbulin (BAL27862)
End point description:	
Terminal half-life	
End point type	Secondary
End point timeframe:	
Day 1 of Cycle 1	

End point values	Phase 1 patients with solid tumors: Lisavanbulin 2 mg	Phase 1 patients with solid tumors: Lisavanbulin 4 mg	Phase 1 patients with solid tumors: Lisavanbulin 8 mg	Phase 1 patients with solid tumors: Lisavanbulin 16 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	7
Units: hour				
median (full range (min-max))	10.3 (5.2 to 20.2)	12.6 (12.3 to 15.7)	13.7 (11.2 to 19.7)	14.8 (9.6 to 21.4)

End point values	Phase 1 patients with solid tumors: Lisavanbulin 20 mg	Phase 1 patients with solid tumors: Lisavanbulin 30 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 8 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 15 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	3	4	3
Units: hour				
median (full range (min-max))	19.3 (10.7 to 30.6)	14.0 (13.4 to 32.4)	12.2 (10.7 to 21.9)	20.6 (18.7 to 20.6)

End point values	Phase 1 patients with GBM / HGG: Lisavanbulin 20 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 25 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 30 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 35 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	3	8	3
Units: hour				
median (full range (min-max))	8.1 (3.9 to 21.3)	11.3 (10.2 to 12.3)	13.9 (9.5 to 35.4)	12.4 (11.5 to 21.3)

End point values	Phase 2a patients with GBM: Lisavanbulin 25 mg			
Subject group type	Reporting group			
Number of subjects analysed	18			
Units: hour				
median (full range (min-max))	12.8 (5.7 to 43.4)			

Statistical analyses

No statistical analyses for this end point

Secondary: Tmax of avanbulin (BAL27862)

End point title	Tmax of avanbulin (BAL27862)
End point description:	
Time to maximum plasma concentration	
End point type	Secondary
End point timeframe:	
Day 1 of Cycle 1	

End point values	Phase 1 patients with solid tumors: Lisavanbulin 2 mg	Phase 1 patients with solid tumors: Lisavanbulin 4 mg	Phase 1 patients with solid tumors: Lisavanbulin 8 mg	Phase 1 patients with solid tumors: Lisavanbulin 16 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	7
Units: hour				
median (full range (min-max))	2.0 (1.1 to 3.0)	1.1 (1.0 to 2.0)	3.0 (1.0 to 4.1)	1.1 (1.0 to 2.2)

End point values	Phase 1 patients with solid tumors: Lisavanbulin 20 mg	Phase 1 patients with solid tumors: Lisavanbulin 30 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 8 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 15 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	3	4	3
Units: hour				
median (full range (min-max))	1.0 (1.0 to 2.1)	2.0 (1.1 to 3.0)	1.5 (1.0 to 2.2)	1.1 (0.8 to 2.0)

End point values	Phase 1 patients with GBM / HGG: Lisavanbulin 20 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 25 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 30 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 35 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	3	8	3
Units: hour				
median (full range (min-max))	1.2 (0.6 to 2.2)	1.0 (1.0 to 2.0)	2.0 (0.5 to 3.0)	2.2 (2.1 to 3.1)

End point values	Phase 2a patients with GBM: Lisavanbulin 25 mg			
Subject group type	Reporting group			
Number of subjects analysed	18			
Units: hour				
median (full range (min-max))	2.0 (0.6 to 3.0)			

Statistical analyses

No statistical analyses for this end point

Secondary: Cmax of avanbulin (BAL27862)

End point title	Cmax of avanbulin (BAL27862)
-----------------	------------------------------

End point description:	
Maximum drug concentration observed in plasma	
End point type	Secondary
End point timeframe:	
Day 1 of Cycle 1	

End point values	Phase 1 patients with solid tumors: Lisavanbulin 2 mg	Phase 1 patients with solid tumors: Lisavanbulin 4 mg	Phase 1 patients with solid tumors: Lisavanbulin 8 mg	Phase 1 patients with solid tumors: Lisavanbulin 16 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	3	7
Units: ng/mL				
geometric mean (geometric coefficient of variation)	6.900 (\pm 0.580)	23.400 (\pm 0.440)	29.190 (\pm 0.490)	120.260 (\pm 0.490)

End point values	Phase 1 patients with solid tumors: Lisavanbulin 20 mg	Phase 1 patients with solid tumors: Lisavanbulin 30 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 8 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 15 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	3	4	3
Units: ng/mL				
geometric mean (geometric coefficient of variation)	116.630 (\pm 0.580)	159.020 (\pm 0.080)	35.260 (\pm 0.560)	75.130 (\pm 0.110)

End point values	Phase 1 patients with GBM / HGG: Lisavanbulin 20 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 25 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 30 mg	Phase 1 patients with GBM / HGG: Lisavanbulin 35 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	3	8	3
Units: ng/mL				
geometric mean (geometric coefficient of variation)	64.110 (\pm 0.460)	103.950 (\pm 0.470)	146.500 (\pm 0.580)	159.100 (\pm 0.650)

End point values	Phase 2a patients with GBM: Lisavanbulin 25 mg			
Subject group type	Reporting group			
Number of subjects analysed	18			
Units: ng/mL				

geometric mean (geometric coefficient of variation)	98.210 (\pm 0.410)			
---	-----------------------	--	--	--

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From first administration of study medication up to 30 days after the last administration.

Adverse event reporting additional description:

Treatment-emergent adverse events and serious adverse events

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25.0
--------------------	------

Reporting groups

Reporting group title	Ph1STC2
-----------------------	---------

Reporting group description:

Ph1 ST - Cohort 2mg/day

Reporting group title	Ph1STC4
-----------------------	---------

Reporting group description:

Ph1 ST - Cohort 4mg/day

Reporting group title	Ph1STC8
-----------------------	---------

Reporting group description:

Ph1 ST - Cohort 8mg/day

Reporting group title	Ph1STC16
-----------------------	----------

Reporting group description:

Ph1 ST - Cohort 16mg/day

Reporting group title	Ph1STC20
-----------------------	----------

Reporting group description:

Ph1 ST - Cohort 20mg/day

Reporting group title	Ph1STC30
-----------------------	----------

Reporting group description:

Ph1 ST - Cohort 30mg/day

Reporting group title	Ph1GBC8
-----------------------	---------

Reporting group description:

Ph1 GBM - Cohort 8mg/day

Reporting group title	Ph1GBC15
-----------------------	----------

Reporting group description:

Ph1 GBM - Cohort 15mg/day

Reporting group title	Ph1GBC20
-----------------------	----------

Reporting group description:

Ph1 GBM - Cohort 20mg/day

Reporting group title	Ph1GBC25
-----------------------	----------

Reporting group description:

Ph1 GBM - Cohort 25mg/day

Reporting group title	Ph1GBC30
-----------------------	----------

Reporting group description:

Ph1 GBM - Cohort 30mg/day

Reporting group title	Ph1GBC35
-----------------------	----------

Reporting group description:

Ph1 GBM - Cohort 35mg/day

Reporting group title	Ph2aC25
-----------------------	---------

Serious adverse events	Ph1STC2	Ph1STC4	Ph1STC8
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 3 (0.00%)	2 / 3 (66.67%)	0 / 3 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Intracranial tumour haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangiocarcinoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disease progression			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral swelling			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gait disturbance			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspiration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hallucination, visual			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hallucination			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Troponin I increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alanine aminotransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral neck fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stoma prolapse			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fractured coccyx			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Ataxia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Somnolence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cognitive disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thalamic infarction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysarthria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Partial seizures			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholangitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Urinary retention			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary incontinence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Muscular weakness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infections and infestations Urinary tract infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0
Sepsis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0
Metabolism and nutrition disorders Hyponatraemia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 3 (0.00%) 0 / 0 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0

Serious adverse events	Ph1STC16	Ph1STC20	Ph1STC30
Total subjects affected by serious adverse events subjects affected / exposed number of deaths (all causes) number of deaths resulting from adverse events	4 / 7 (57.14%) 0 0	5 / 7 (71.43%) 0 0	1 / 3 (33.33%) 0 0
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Intracranial tumour haemorrhage subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 7 (0.00%) 0 / 0 0 / 0	0 / 7 (0.00%) 0 / 0 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0
Cholangiocarcinoma subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 7 (14.29%) 0 / 1 0 / 0	0 / 7 (0.00%) 0 / 0 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 7 (0.00%) 0 / 0 0 / 0	0 / 7 (0.00%) 0 / 0 0 / 0	0 / 3 (0.00%) 0 / 0 0 / 0
Disease progression			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral swelling			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gait disturbance			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspiration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			

Confusional state			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hallucination, visual			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hallucination			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Troponin I increased			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alanine aminotransferase increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Accidental overdose			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral neck fracture			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stoma prolapse			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fractured coccyx			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Ataxia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Somnolence			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cognitive disorder			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thalamic infarction			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysarthria			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Partial seizures			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Intestinal obstruction			

subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	2 / 7 (28.57%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholangitis			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Urinary retention			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary incontinence			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Muscular weakness			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	0 / 7 (0.00%)	2 / 7 (28.57%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Ph1GBC8	Ph1GBC15	Ph1GBC20
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	2 / 7 (28.57%)
number of deaths (all causes)	0	0	1
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Intracranial tumour haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangiocarcinoma			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disease progression			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral swelling			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gait disturbance			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			

Dyspnoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspiration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hallucination, visual			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hallucination			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Troponin I increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alanine aminotransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Aspartate aminotransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral neck fracture			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stoma prolapse			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fractured coccyx			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Ataxia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Somnolence			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cognitive disorder			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thalamic infarction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysarthria			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Partial seizures			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Intestinal obstruction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			

Cholangitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Urinary retention			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary incontinence			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Muscular weakness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Ph1GBC25	Ph1GBC30	Ph1GBC35
Total subjects affected by serious adverse events			

subjects affected / exposed	1 / 3 (33.33%)	4 / 8 (50.00%)	2 / 3 (66.67%)
number of deaths (all causes)	0	1	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Intracranial tumour haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangiocarcinoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disease progression			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral swelling			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gait disturbance			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	2 / 3 (66.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspiration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	2 / 3 (66.67%)
occurrences causally related to treatment / all	0 / 0	0 / 1	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hallucination, visual			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hallucination			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Investigations			
Troponin I increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alanine aminotransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral neck fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stoma prolapse			
subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fractured coccyx			
subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Ataxia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Somnolence			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cognitive disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			

subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thalamic infarction			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysarthria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Partial seizures			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholangitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Urinary retention			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary incontinence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Muscular weakness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Ph2aC25		
Total subjects affected by serious adverse events			
subjects affected / exposed	8 / 18 (44.44%)		
number of deaths (all causes)	7		
number of deaths resulting from adverse events	1		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Intracranial tumour haemorrhage			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholangiocarcinoma			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Disease progression			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Peripheral swelling			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gait disturbance			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General physical health deterioration			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pain			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aspiration			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Confusional state			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Delirium			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hallucination, visual			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hallucination			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
Troponin I increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Alanine aminotransferase increased			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Femoral neck fracture			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Stoma prolapse			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fall			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Humerus fracture			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Fractured coccyx			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Ataxia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Somnolence			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cognitive disorder			

subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ischaemic stroke			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Headache			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Seizure			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Thalamic infarction			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dysarthria			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Partial seizures			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Intestinal obstruction			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Constipation			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal pain			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematemesis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nausea			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholangitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Urinary retention			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary incontinence			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue			

disorders			
Muscular weakness			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Hyponatraemia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Ph1STC2	Ph1STC4	Ph1STC8
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 3 (100.00%)	3 / 3 (100.00%)	3 / 3 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Benign neoplasm			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Metastases to meninges			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Haemangioma of liver			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin papilloma			

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Tumour pain subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1
Vascular disorders			
Hypotension subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Hot flush subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Hypertension subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1
General disorders and administration site conditions			
Chills subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Fatigue subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	1 / 3 (33.33%) 1	1 / 3 (33.33%) 1
Pyrexia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Early satiety subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Unevaluable event subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Gait disturbance subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Oedema peripheral			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
General physical health deterioration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Localised oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Reproductive system and breast disorders			
Acquired phimosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Erectile dysfunction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vaginal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Productive cough			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 3 (66.67%)
occurrences (all)	0	0	2
Dyspnoea exertional			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	1	0	1
Cough			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Pleuritic pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Psychiatric disorders			
Depressed mood			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hallucination			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Disorientation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Psychomotor retardation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Libido decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Agitation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Somnambulism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Confusional state			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hallucination, visual			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Investigations			
Blood bilirubin increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram abnormal			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Alanine aminotransferase increased			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood glucose increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neutrophil count increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Troponin increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lipase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Troponin T increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
White blood cell count increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			

Fall			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Skin laceration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Myocardial ischaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Ventricular extrasystoles			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sinus tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ventricular arrhythmia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sinus bradycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			

Amnesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Brain oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dysarthria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Aphasia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Balance disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Facial paralysis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hemianopia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lethargy			
subjects affected / exposed	0 / 3 (0.00%)	2 / 3 (66.67%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Disturbance in attention			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Coordination abnormal			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Migraine			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0

Meralgia paraesthetica			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neuralgia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Hyporesponsive to stimuli			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Memory impairment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cognitive disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hemiparesis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sensory loss			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Seizure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Partial seizures			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 3 (66.67%)
occurrences (all)	0	0	2
Restless legs syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Neurologic neglect syndrome subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Neuropathy peripheral subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Tremor subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Peroneal nerve palsy subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Sciatica subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Blood and lymphatic system disorders			
Neutropenia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Neutrophilia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Anaemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1	0 / 3 (0.00%) 0
Thrombocytopenia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Ear and labyrinth disorders			
Tinnitus subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Vertigo subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Otorrhoea			

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Ear pain subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Eye disorders Visual impairment subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Vitreous floaters subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Cataract subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Blepharitis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Eye pain subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Cataract subcapsular subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Gastrointestinal disorders Abdominal discomfort subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Anal incontinence subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0
Abdominal pain lower			

subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Abdominal pain			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Mouth ulceration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	2 / 3 (66.67%)
occurrences (all)	3	0	2
Constipation			
subjects affected / exposed	0 / 3 (0.00%)	2 / 3 (66.67%)	1 / 3 (33.33%)
occurrences (all)	0	3	2
Intestinal fistula			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lip dry			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Dysphagia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Defaecation urgency			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rectal perforation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vomiting			

subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Epigastric discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	1 / 3 (33.33%)
occurrences (all)	1	1	1
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Hepatic cyst			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperbilirubinaemia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Hair growth abnormal			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cold sweat			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hair colour changes			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Rash maculo-papular			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Pruritus			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Night sweats			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin disorder			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Skin ulcer			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Xeroderma			

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 3 (0.00%) 0	1 / 3 (33.33%) 1
Renal and urinary disorders			
Bladder discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Renal colic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Polyuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Calculus urinary			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Micturition urgency			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nephrolithiasis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nocturia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			

Joint swelling			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Arthralgia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Back pain			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	1	0	1
Sacral pain			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Limb discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
COVID-19			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Escherichia urinary tract infection			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lip infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Fungal infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Candida infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hordeolum			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Lower respiratory tract infection			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Viral infection			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Oral candidiasis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Skin infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypoglycaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Hypocalcaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyponatraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vitamin B12 deficiency			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypophagia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Hyperglycaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypercalcaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperphosphataemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Ph1STC16	Ph1STC20	Ph1STC30
Total subjects affected by non-serious adverse events			
subjects affected / exposed	6 / 7 (85.71%)	7 / 7 (100.00%)	3 / 3 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Benign neoplasm			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Metastases to meninges			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Haemangioma of liver			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin papilloma			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tumour pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			

Hypotension subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Hot flush subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Hypertension subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 2	1 / 7 (14.29%) 2	0 / 3 (0.00%) 0
General disorders and administration site conditions			
Chills subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 3 (0.00%) 0
Fatigue subjects affected / exposed occurrences (all)	3 / 7 (42.86%) 3	3 / 7 (42.86%) 3	0 / 3 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Early satiety subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 3 (0.00%) 0
Unevaluable event subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 3 (0.00%) 0
Gait disturbance subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Oedema peripheral subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 3 (0.00%) 0
General physical health deterioration subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Localised oedema			

subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Reproductive system and breast disorders			
Acquired phimosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Erectile dysfunction			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vaginal haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Respiratory, thoracic and mediastinal disorders			
Productive cough			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dyspnoea exertional			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Oropharyngeal pain			
subjects affected / exposed	1 / 7 (14.29%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Epistaxis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	1 / 7 (14.29%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Pleuritic pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			

subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Psychiatric disorders			
Depressed mood			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Hallucination			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Depression			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Disorientation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Psychomotor retardation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Libido decreased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Agitation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Somnambulism			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Confusional state			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1

Hallucination, visual subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	1 / 3 (33.33%) 1
Investigations			
Blood bilirubin increased subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Electrocardiogram abnormal subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	2 / 7 (28.57%) 2	0 / 3 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 2	3 / 7 (42.86%) 3	0 / 3 (0.00%) 0
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 2	3 / 7 (42.86%) 3	0 / 3 (0.00%) 0
Blood glucose increased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Neutrophil count decreased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Lymphocyte count decreased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Blood creatine phosphokinase decreased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Blood creatine phosphokinase			

increased			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Blood creatinine increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neutrophil count increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Troponin increased			
subjects affected / exposed	0 / 7 (0.00%)	2 / 7 (28.57%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Lipase increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Troponin T increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
White blood cell count increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Procedural pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin laceration			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Myocardial ischaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ventricular extrasystoles			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Sinus tachycardia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ventricular arrhythmia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Sinus bradycardia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Amnesia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Brain oedema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dysarthria			

subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Aphasia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Balance disorder			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Facial paralysis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hemianopia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lethargy			
subjects affected / exposed	1 / 7 (14.29%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Disturbance in attention			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Dizziness			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Coordination abnormal			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Migraine			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Meralgia paraesthetica			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neuralgia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyporesponsive to stimuli			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Memory impairment			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cognitive disorder			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Hemiparesis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sensory loss			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Seizure			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Partial seizures			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
Restless legs syndrome			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neurologic neglect syndrome			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Tremor			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Peroneal nerve palsy			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neutrophilia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Anaemia			
subjects affected / exposed	0 / 7 (0.00%)	2 / 7 (28.57%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Thrombocytopenia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Tinnitus			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Otorrhoea			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ear pain			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Eye disorders			

Visual impairment subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Vitreous floaters subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Cataract subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Blepharitis subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 3 (0.00%) 0
Eye pain subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Cataract subcapsular subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Gastrointestinal disorders			
Abdominal discomfort subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 2	0 / 3 (0.00%) 0
Anal incontinence subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 3 (0.00%) 0
Abdominal pain lower subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 3 (0.00%) 0
Abdominal pain subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	2 / 7 (28.57%) 2	0 / 3 (0.00%) 0
Mouth ulceration			

subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Diarrhoea			
subjects affected / exposed	0 / 7 (0.00%)	3 / 7 (42.86%)	1 / 3 (33.33%)
occurrences (all)	0	5	1
Constipation			
subjects affected / exposed	1 / 7 (14.29%)	3 / 7 (42.86%)	1 / 3 (33.33%)
occurrences (all)	1	3	1
Intestinal fistula			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Lip dry			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dysphagia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Defaecation urgency			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Rectal perforation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	1 / 7 (14.29%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Oral pain			

subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Epigastric discomfort			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Nausea			
subjects affected / exposed	2 / 7 (28.57%)	3 / 7 (42.86%)	0 / 3 (0.00%)
occurrences (all)	2	4	0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Hepatobiliary disorders			
Hepatic cyst			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Palmar-plantar erythrodysesthesia syndrome			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hair growth abnormal			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Cold sweat			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Hair colour changes			

subjects affected / exposed	0 / 7 (0.00%)	2 / 7 (28.57%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Dry skin			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 7 (0.00%)	2 / 7 (28.57%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Night sweats			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin disorder			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin ulcer			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Xeroderma			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Bladder discomfort			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Renal colic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Polyuria			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Calculus urinary			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Micturition urgency			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nephrolithiasis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nocturia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
Joint swelling			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Arthralgia			
subjects affected / exposed	1 / 7 (14.29%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Back pain			

subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Sacral pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Limb discomfort			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Muscular weakness			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Neck pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal discomfort			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Lip infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Fungal infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Candida infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hordeolum			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Viral infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Oral candidiasis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypoglycaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			
subjects affected / exposed	2 / 7 (28.57%)	3 / 7 (42.86%)	0 / 3 (0.00%)
occurrences (all)	3	3	0
Hypocalcaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyponatraemia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	2 / 3 (66.67%)
occurrences (all)	0	2	2
Vitamin B12 deficiency			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypophagia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypercalcaemia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Hypokalaemia			

subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	2 / 3 (66.67%)
occurrences (all)	1	0	2
Vitamin D deficiency			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperphosphataemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Ph1GBC8	Ph1GBC15	Ph1GBC20
Total subjects affected by non-serious adverse events			
subjects affected / exposed	4 / 4 (100.00%)	3 / 3 (100.00%)	5 / 7 (71.43%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Benign neoplasm			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Metastases to meninges			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Haemangioma of liver			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Skin papilloma			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Tumour pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hypotension			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Hot flush			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hypertension			

subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0
General disorders and administration site conditions			
Chills			
subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0
Fatigue			
subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	2 / 3 (66.67%) 2	3 / 7 (42.86%) 4
Pyrexia			
subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0
Early satiety			
subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0
Unevaluable event			
subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0
Gait disturbance			
subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0
Oedema peripheral			
subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0
General physical health deterioration			
subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0
Localised oedema			
subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0
Reproductive system and breast disorders			
Acquired phimosis			
subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0
Erectile dysfunction			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Vaginal haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Productive cough			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dyspnoea exertional			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Epistaxis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Pleuritic pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Depressed mood			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hallucination			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Disorientation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Psychomotor retardation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Libido decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	1 / 4 (25.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)
occurrences (all)	1	1	0
Agitation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Somnambulism			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Confusional state			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Hallucination, visual			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Investigations			
Blood bilirubin increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Electrocardiogram abnormal			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Alanine aminotransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Blood glucose increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			

subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Neutrophil count increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Troponin increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Lipase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Troponin T increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
White blood cell count increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	3 / 4 (75.00%)	1 / 3 (33.33%)	1 / 7 (14.29%)
occurrences (all)	3	2	1
Procedural pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			

Myocardial ischaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Ventricular extrasystoles			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Sinus tachycardia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Palpitations			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Ventricular arrhythmia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Sinus bradycardia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Amnesia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Brain oedema			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dysarthria			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Aphasia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
Balance disorder			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Facial paralysis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hemianopia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Lethargy			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	1 / 7 (14.29%)
occurrences (all)	0	1	1
Disturbance in attention			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Coordination abnormal			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Migraine			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Meralgia paraesthetica			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Neuralgia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hyporesponsive to stimuli			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Memory impairment			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Cognitive disorder			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 4 (0.00%)	2 / 3 (66.67%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Hemiparesis			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
Sensory loss			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Seizure			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	2 / 7 (28.57%)
occurrences (all)	2	0	6
Partial seizures			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Headache			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
Restless legs syndrome			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Neurologic neglect syndrome			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Neuropathy peripheral			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	1 / 4 (25.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)
occurrences (all)	1	1	0
Peroneal nerve palsy			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Sciatica			

subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Neutrophilia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Anaemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	1 / 7 (14.29%)
occurrences (all)	0	1	1
Thrombocytopenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Tinnitus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Otorrhoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Ear pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Visual impairment			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Vitreous floaters			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Cataract			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Blepharitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Eye pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Cataract subcapsular			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Anal incontinence			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Abdominal pain lower			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	2 / 7 (28.57%)
occurrences (all)	1	0	2
Constipation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Intestinal fistula			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Lip dry			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dysphagia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Defaecation urgency			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Stomatitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rectal perforation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Epigastric discomfort			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Nausea subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	1 / 7 (14.29%) 1
Gastrointestinal haemorrhage subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0
Hepatobiliary disorders			
Hepatic cyst subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0
Hyperbilirubinaemia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0
Skin and subcutaneous tissue disorders			
Alopecia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0
Palmar-plantar erythrodysaesthesia syndrome subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0
Hair growth abnormal subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0
Cold sweat subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0
Hair colour changes subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0
Dry skin subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0
Rash maculo-papular subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 3 (0.00%) 0	0 / 7 (0.00%) 0
Pruritus			

subjects affected / exposed	0 / 4 (0.00%)	1 / 3 (33.33%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Night sweats			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Skin disorder			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Skin ulcer			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Xeroderma			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Bladder discomfort			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Renal colic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Polyuria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Calculus urinary			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Pollakiuria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Haematuria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Micturition urgency			
subjects affected / exposed	0 / 4 (0.00%)	2 / 3 (66.67%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Urinary incontinence			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Nephrolithiasis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Nocturia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Joint swelling			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Arthralgia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
Back pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Sacral pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Limb discomfort			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Neck pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Pain in extremity			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal discomfort			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Lip infection			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Fungal infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Nasopharyngitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Oral herpes			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Candida infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Rhinitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hordeolum			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Viral infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Dehydration			

subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hypoglycaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Hypocalcaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hyponatraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Vitamin B12 deficiency			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hypophagia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Hypercalcaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 3 (0.00%)	1 / 7 (14.29%)
occurrences (all)	2	0	1
Vitamin D deficiency			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Hyperphosphataemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 3 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Ph1GBC25	Ph1GBC30	Ph1GBC35
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 3 (100.00%)	7 / 8 (87.50%)	3 / 3 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Benign neoplasm			
subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Metastases to meninges			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Haemangioma of liver			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin papilloma			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Tumour pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Hypertension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Chills			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	2 / 3 (66.67%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0

Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Early satiety			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Unevaluable event			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gait disturbance			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Oedema peripheral			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
General physical health deterioration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Localised oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Acquired phimosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Erectile dysfunction			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Vaginal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Productive cough			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dyspnoea exertional			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Pleuritic pain			
subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Dyspnoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Depressed mood			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hallucination			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Depression			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Disorientation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Psychomotor retardation subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Libido decreased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 8 (12.50%) 1	0 / 3 (0.00%) 0
Insomnia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	2 / 8 (25.00%) 2	1 / 3 (33.33%) 1
Agitation subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 8 (12.50%) 1	1 / 3 (33.33%) 1
Somnambulism subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Confusional state subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 8 (12.50%) 1	0 / 3 (0.00%) 0
Hallucination, visual subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Investigations			
Blood bilirubin increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Electrocardiogram abnormal subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	3 / 8 (37.50%) 5	0 / 3 (0.00%) 0
Aspartate aminotransferase increased			

subjects affected / exposed	1 / 3 (33.33%)	2 / 8 (25.00%)	0 / 3 (0.00%)
occurrences (all)	1	2	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Blood glucose increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 3 (33.33%)	1 / 8 (12.50%)	1 / 3 (33.33%)
occurrences (all)	2	1	1
Blood creatinine increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neutrophil count increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Troponin increased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Lipase increased			

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Troponin T increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
White blood cell count increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Weight decreased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Injury, poisoning and procedural complications			
Fall subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	1 / 3 (33.33%) 1
Procedural pain subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Skin laceration subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Contusion subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Cardiac disorders			
Myocardial ischaemia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Ventricular extrasystoles subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Sinus tachycardia			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ventricular arrhythmia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sinus bradycardia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Nervous system disorders			
Amnesia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Brain oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dysarthria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Aphasia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Balance disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Facial paralysis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hemianopia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lethargy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Disturbance in attention subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 8 (12.50%) 1	0 / 3 (0.00%) 0
Coordination abnormal subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Migraine subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Meralgia paraesthetica subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Neuralgia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 8 (12.50%) 1	0 / 3 (0.00%) 0
Hyporesponsive to stimuli subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Memory impairment subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 8 (12.50%) 1	0 / 3 (0.00%) 0
Cognitive disorder subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Paraesthesia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Hemiparesis subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Sensory loss subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0

Seizure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Partial seizures			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Headache			
subjects affected / exposed	1 / 3 (33.33%)	1 / 8 (12.50%)	1 / 3 (33.33%)
occurrences (all)	1	1	1
Restless legs syndrome			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Neurologic neglect syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Tremor			
subjects affected / exposed	0 / 3 (0.00%)	2 / 8 (25.00%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Peroneal nerve palsy			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Sciatica			
subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	0	3	0
Neutrophilia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Anaemia			

subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Thrombocytopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Tinnitus			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Vertigo			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Otorrhoea			
subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Ear pain			
subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Eye disorders			
Visual impairment			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vitreous floaters			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cataract			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Blepharitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eye pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cataract subcapsular			

subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Anal incontinence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abdominal pain lower			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	2 / 3 (66.67%)
occurrences (all)	0	0	2
Mouth ulceration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences (all)	1	0	1
Intestinal fistula			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lip dry			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dysphagia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Dry mouth			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Defaecation urgency			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rectal perforation			
subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Vomiting			
subjects affected / exposed	1 / 3 (33.33%)	1 / 8 (12.50%)	1 / 3 (33.33%)
occurrences (all)	1	1	1
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Epigastric discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	2 / 3 (66.67%)	1 / 8 (12.50%)	1 / 3 (33.33%)
occurrences (all)	2	1	1
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Hepatic cyst			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	2 / 3 (66.67%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hair growth abnormal			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cold sweat			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hair colour changes			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
Pruritus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Petechiae			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin ulcer			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Xeroderma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Bladder discomfort			
subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Renal colic			
subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Polyuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Calculus urinary			
subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Pollakiuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0

Micturition urgency subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Urinary incontinence subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	1 / 8 (12.50%) 1	0 / 3 (0.00%) 0
Nephrolithiasis subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 2	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Nocturia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Joint swelling subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Arthralgia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Sacral pain subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Limb discomfort subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Muscular weakness subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Neck pain subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 8 (0.00%) 0	0 / 3 (0.00%) 0
Pain in extremity			

subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Muscle spasms			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
COVID-19			
subjects affected / exposed	1 / 3 (33.33%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	3	2	0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Lip infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Fungal infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Cystitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Candida infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Rhinitis			
subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Upper respiratory tract infection			
subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	3	0	0
Hordeolum			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Viral infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypoglycaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			

subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Hypocalcaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyponatraemia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Vitamin B12 deficiency			
subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Hypophagia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Hyperglycaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypercalcaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	2 / 3 (66.67%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	2	1	0
Vitamin D deficiency			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hyperphosphataemia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0

Non-serious adverse events	Ph2aC25		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	18 / 18 (100.00%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Benign neoplasm			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Metastases to meninges			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Haemangioma of liver			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Skin papilloma			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Tumour pain			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Hot flush			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Hypertension			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	3		
General disorders and administration site conditions			
Chills			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Fatigue			
subjects affected / exposed	8 / 18 (44.44%)		
occurrences (all)	10		
Pyrexia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Early satiety			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Unevaluable event			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Gait disturbance			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	3		
Oedema peripheral			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
General physical health deterioration			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Localised oedema			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Reproductive system and breast disorders			
Acquired phimosis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Erectile dysfunction			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Vaginal haemorrhage			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Productive cough			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Rhinorrhoea			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Dyspnoea exertional			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Oropharyngeal pain			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Epistaxis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Cough			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Pleuritic pain			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Dyspnoea			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			
Depressed mood			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Hallucination			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Depression			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Disorientation			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Anxiety			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Psychomotor retardation			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		

Libido decreased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Insomnia			
subjects affected / exposed	6 / 18 (33.33%)		
occurrences (all)	6		
Agitation			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Somnambulism			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Confusional state			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Hallucination, visual			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Investigations			
Blood bilirubin increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Gamma-glutamyltransferase increased			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Electrocardiogram abnormal			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Alanine aminotransferase increased			
subjects affected / exposed	4 / 18 (22.22%)		
occurrences (all)	5		
Aspartate aminotransferase increased			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	3		
Blood alkaline phosphatase increased			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Blood glucose increased			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Neutrophil count decreased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Lymphocyte count decreased			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Blood creatine phosphokinase decreased			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Blood creatine phosphokinase increased			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Blood creatinine increased			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
White blood cell count decreased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Neutrophil count increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Troponin increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Lipase increased			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	2		
Troponin T increased			

subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
White blood cell count increased			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	2		
Weight decreased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	8		
Procedural pain			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Skin laceration			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Contusion			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Cardiac disorders			
Myocardial ischaemia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Tachycardia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Ventricular extrasystoles			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Sinus tachycardia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Palpitations			

subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	2		
Ventricular arrhythmia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Sinus bradycardia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Amnesia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Brain oedema			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Dysarthria			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Aphasia			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	4		
Balance disorder			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Facial paralysis			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Hemianopia			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Lethargy			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	3		
Disturbance in attention			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		

Dizziness			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	2		
Coordination abnormal			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Migraine			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Meralgia paraesthetica			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Neuralgia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Hyporesponsive to stimuli			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Memory impairment			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Cognitive disorder			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Paraesthesia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Hemiparesis			
subjects affected / exposed	4 / 18 (22.22%)		
occurrences (all)	4		
Sensory loss			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Seizure			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	6		

Partial seizures			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Headache			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	4		
Restless legs syndrome			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Neurologic neglect syndrome			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Neuropathy peripheral			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Tremor			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Peroneal nerve palsy			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Sciatica			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Neutrophilia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	2		
Anaemia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Thrombocytopenia			

subjects affected / exposed occurrences (all)	2 / 18 (11.11%) 2		
Ear and labyrinth disorders			
Tinnitus			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Vertigo			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Otorrhoea			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Ear pain			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Eye disorders			
Visual impairment			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Vitreous floaters			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Cataract			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Blepharitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Eye pain			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Cataract subcapsular			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			

Abdominal discomfort			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Anal incontinence			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Abdominal pain upper			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Abdominal pain lower			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Abdominal pain			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Mouth ulceration			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Diarrhoea			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Constipation			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	3		
Intestinal fistula			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Lip dry			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Dysphagia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Dry mouth			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		

Defaecation urgency			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Stomatitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Rectal perforation			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Vomiting			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Gastrooesophageal reflux disease			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Oral pain			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Epigastric discomfort			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Rectal haemorrhage			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Nausea			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Hepatobiliary disorders			
Hepatic cyst			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Hyperbilirubinaemia			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Hair growth abnormal			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Cold sweat			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Hair colour changes			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Dry skin			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Rash maculo-papular			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Pruritus			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Night sweats			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Petechiae			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Skin disorder			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Skin ulcer			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Urticaria			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Rash			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Xeroderma			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Renal and urinary disorders			
Bladder discomfort			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Renal colic			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Polyuria			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Calculus urinary			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Pollakiuria			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Haematuria			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Micturition urgency			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		

Urinary incontinence			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Nephrolithiasis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Nocturia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			
Joint swelling			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Arthralgia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Back pain			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Sacral pain			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Limb discomfort			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Muscular weakness			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Neck pain			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Pain in extremity			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Musculoskeletal discomfort			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Musculoskeletal chest pain			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Muscle spasms			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	3		
Infections and infestations			
COVID-19			
subjects affected / exposed	4 / 18 (22.22%)		
occurrences (all)	4		
Escherichia urinary tract infection			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Gastroenteritis viral			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Lip infection			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Fungal infection			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Cystitis			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	4		
Nasopharyngitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Oral herpes			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Candida infection			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		

Rhinitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Upper respiratory tract infection			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Hordeolum			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Lower respiratory tract infection			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Urinary tract infection			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Viral infection			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Oral candidiasis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Skin infection			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Hypoglycaemia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Decreased appetite			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Hypocalcaemia			

subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Hyponatraemia			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	6		
Vitamin B12 deficiency			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Hypophagia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Hyperglycaemia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Hypercalcaemia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Hypokalaemia			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Vitamin D deficiency			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Hyperphosphataemia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
06 July 2016	Enrollment of patients with glioblastoma or high-grade glioma as separate dose cohorts. Option to implement a twice-daily dosing regimen. Changes in biomarker assessments.
14 December 2016	Packaging of future batches of lisavanbulin capsules (1 mg and 5 mg) in brown glass bottles or plastic (HDPE) bottles.
22 June 2017	Requirement for serum sodium to be documented to be institutional LLN at screening. Review of safety laboratory parameters at investigator and pharmacy levels prior to dispensing of new study medication.
28 May 2018	Update to the sponsor's pharmacovigilance service provider.
23 March 2020	Changes in response to the COVID-19 pandemic, consistent with the NHS Guidance COVID-19: Guidance for sponsors, sites and researchers (v2.1 20 March 2020).
30 March 2020	Modification of the Phase 2a design, and associated changes, following completion of the Phase 1 portion of the study. Phase 2a to continue in patients with recurrent GBM only whose GBM tumor tissue was positive for end-binding protein 1 (EB1).
09 April 2021	Addition of a cumulative safety evaluation. Introduction of a survival follow-up. Alignment of inclusion criterion 7 with the CTFG contraception guidance. Removal of references to patients not qualified or incapable of giving legal consent.
01 July 2021	Alignment of Protocol Section 6.3 with storage conditions outlined in the IMPD. Clarification of Protocol Inclusion criterion 7 consistent with Section 4.3 of the CTFG guidance Recommendations related to contraception and pregnancy testing in clinical trials Version 1.1 (CTFG 21/09/2020).

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported